Summarized by Masters of Longevity from M Ventures.
TRIMTECH and Biogen announced a collaboration to develop CNS-active protein degraders.

Key Takeaways
- TRIMTECH and Biogen will collaborate to develop degraders.
- TRIMTECH's TRIM21 degraders are reported to reach the CNS.
- The agreement may provide up to $411 million plus royalties.



